Drug intelligence / Profile preview

alpha-cyperone

Development stage
Preclinical
Modality
Small Molecules
Administration
In Vitro (research Context), No Clinical Human Routes Established
01

Overview

**alpha-cyperone** is a naturally occurring sesquiterpene majorly found in Cyperus rotundus and other plants. It has demonstrated a wide range of pharmacological activities: - **Antidepressant-like effects** through modulation of SIRT3/ROS/NF-κB signaling and suppression of NLRP3 inflammasome, leading to enhanced neuroplasticity. - **Anti-inflammatory effects** mediated by reduced expression of COX-2 and IL-6 via NF-κB pathway. - **Antifungal activity**, particularly fungicidal effects against Cryptococcus neoformans and Candida krusei, and synergistic action when combined with fluconazole through possible ROS-mediated pathways. - **Cell protection** against oxidative stress-induced damage and apoptosis in neuronal cells, attributed to reduced ROS production. - **Inhibition of virulence factors** such as capsule synthesis in pathogenic fungi and Hla production in Staphylococcus aureus, suggesting antimicrobial potential. It is not classified as a pharmaceutical drug and is primarily a research chemical with bioactive properties.

Other names
α-cyperone(+)-alpha-cyperoneA-CYPERONECyperoneα-cyperon473-08-5(4aS,7R)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one4,11-selinadien-3-one
02

Targets

RELA (Nuclear Factor Kappa B Subunit p65)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)JNK (Mitogen-activated protein kinase kinase kinase family)ERKRK (Ribokinase)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on alpha-cyperone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-cyperone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call